Your browser doesn't support javascript.
loading
Cognitive Outcome after Acute Spontaneous Intracerebral Hemorrhage: Analysis of the iDEF Randomized Trial.
Lioutas, Vasileios-Arsenios; Katsanos, Aristeidis H; Shoamanesh, Ashkan; Vahidy, Farhaan; Heistand, Elizabeth C; Foster, Lydia D; Yeatts, Sharon D; Selim, Magdy.
Afiliação
  • Lioutas VA; Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Katsanos AH; Division of Neurology, McMaster University/Population Health Research Institute, Hamilton, Ontario, Canada.
  • Shoamanesh A; Division of Neurology, McMaster University/Population Health Research Institute, Hamilton, Ontario, Canada.
  • Vahidy F; Department of Neurosurgery Houston Methodist, Houston, Texas, USA.
  • Heistand EC; Department of Population Health Sciences Weill Cornell Medicine, New York, New York, USA.
  • Foster LD; Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Yeatts SD; Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Selim M; Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Cerebrovasc Dis ; : 1-9, 2024 Apr 05.
Article em En | MEDLINE | ID: mdl-38583421
ABSTRACT

INTRODUCTION:

The impact of intracerebral hemorrhage (ICH) on cognition and the determinants of cognitive recovery early after ICH remain elusive. In this post hoc analysis of the intracerebral hemorrhage deferoxamine (iDEF) trial, we examined the trajectories of cognitive impairment and the determinants of early cognitive recovery after ICH.

METHODS:

We examined baseline factors associated with a 90-day cognitive outcome and constructed generalized linear mixed models to examine the trajectory of cognitive function over time among iDEF participants. Cognition was measured by the Montreal Cognitive Assessment (MoCA) scores on days 7, 30, and 90.

RESULTS:

291 were available for analysis under the trial's modified intention-to-treat definition (38% female, mean age 60.3 ± 12.0 years, median NIHSS 13, IQR 8-18). The median baseline ICH volume was 12.9 IQR (6.4-26.0) mL; 59 (20%) of the ICH cases were lobar, 120 (41%) had intraventricular extension. There was an overall significant increase in total MOCA score with time (p < 0.0001). Total MOCA score increased by an estimated 3.9 points (95% CI 3.1, 4.7) between the day 7 and day 30 assessments and by an additional 2.9 points (95% CI 2.2, 3.6) between the day 30 and day 90 assessments. Despite the overall improvement, 134 of 205 (65%) patients with an available 90-day MoCA score remained cognitively impaired with a score <26 on day 90. Older age, higher NIHSS score, baseline ICH volume, intraventricular hemorrhage, and perihematoma edema had an adjusted negative impact on cognitive recovery.

CONCLUSIONS:

Although ICH survivors exhibit significant improvement of cognitive status over the first 3 months, cognitive performance remains impaired in the majority of patients. Among factors independently associated with worse cognitive recovery, higher baseline ICH, intraventricular blood and perihematomal edema volumes, are potential therapeutic targets that merit further exploration.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article